SU056 (SU-056) is a specific small molecule that potently inhibits tumor growth and progression via Y box binding protein 1 (YBX1, YB1) inhibition.
SU056 inhibits cell proliferation, resistance to apoptosis in ovarian cancer (OC) cells, and arrests in the G1 phase.
SU056 (1-10 uM) strongly inhibits YB-1 expression, SU056 broadly inhibits YB-1 across different OC cell lines with IC50 of 5.6, 3.2, 3.7 uM against OVCAR4, OVCAR8, and SKOV3 cells.
SU056 treatment leads to enrichment of proteins associated with apoptosis and RNA degradation pathways while downregulating spliceosome pathway.
SU056 independently restrains OC progression and exerts a synergistic effect with paclitaxel to further reduce disease progression with no observable liver toxicity.
SU056 showed delayed disease progression via inhibition of drug efflux and multidrug resistance 1, and significantly lower neurotoxicity as compared with etoposide.